| FGF9 — Glial-Activating Factor | |
|---|---|
| Protein Name | FGF9 |
| Gene | [FGF9](/genes/fgf9) |
| UniProt ID | P31360 |
| Molecular Weight | ~23 kDa (208 amino acids) |
| Subcellular Localization | Secreted, Extracellular space |
| Protein Family | FGF (Fibroblast Growth Factor) family |
| Structure | Beta-trefoil fold |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers), [Parkinson's Disease](/diseases/parkinsons-disease), Multiple Sclerosis |
Fgf9 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
FGF9 (Fibroblast Growth Factor 9), also known as Glial-Activating Factor (GAF), is a member of the FGF family of growth factors. Encoded by the FGF9 gene, this protein is notable for its unique receptor binding profile and its role in glial cell biology [1][2].
FGF9 was originally identified for its ability to stimulate the proliferation of glial cells, particularly astrocytes and Schwann cells. This activity led to its designation as Glial-Activating Factor [3].
Like other FGFs, FGF9 adopts the characteristic beta-trefoil structure:
FGFR3 Specificity
Heparin Independence
FGF9 activates:
FGF9 in AD:
Astrogliosis
Neuroinflammation
In PD:
FGF9 in MS:
The study of Fgf9 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.